[…]
Triple Hair Group receives Health Canada approval to start Phase III clinical trials on its Therapy-07 prescription drug in Canada
[…]
[…]
[…]
[…]
Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has entered into a strategic licensing agreement with Pharmacy Solutions to compound Triple Hair’s hair growth products in the United States. Alopecia is an under-served global market of USD 7.8 billion in 2021, estimated to reach USD 14.2 billion in 2028. […]
The Company offers a patented, clinically proven and safe formula for the treatment of androgenic alopecia in women, a large underserved market […]
Physician-developed medical hair growth products for men shown to be more effective than known brands. […]
Triple Hair Group Inc. is pleased to announce that Robert Y. Girard, who has 35-year experience in business law and capital markets, and Luc Tanguay, a veteran of two decades of experience in the biotech industry, have joined the Company board as independent directors. […]
Since our last communication, we have made significant progress and achieved many goals we set for 2021. This update is about Triple Hair Group’s latest and ongoing activities, as well as what’s in store for 2021-2022. […]
We are pleased to report that Triple Hair has been selected as one of 30 finalists to present at BIO Digital’s Start-Up Stadium by a panel of leading experts from the world’s best pharmaceutical, venture capital and law firms. […]